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Abstract
Background: Identifying optimal, post-operative opioid management strategies is a priority of health providers and
government agencies. At present, there are no studies we are aware of that have formally investigated opioid
prescribing patterns for post-operative non-arthroplasty orthopedic conditions such as femoroacetabular impingement,
nor has any study investigated the influence of opioid prescription patterns on health care costs and utilization. We
aimed to investigate a subgrouping scheme associated with post-operative opioid prescription strategies and measure
the subgroups’ direct and indirect health care utilization and costs in individuals undergoing non-arthroplasty orthopedic
hip surgery.
Methods: The study was an observational cohort of routine military clinical practices. We used cluster analysis to
characterize pre-operative (12 months) and post-operative (24 months) opioid prescription patterns. Linear mixed
effects modeling (with statistical controls for baseline status) identified opioid prescription pattern subgroups and
identified subgroup differences in health care utilization and costs.
Results: Two distinct clusters were identified representing 1) short-duration, high total days’ supply (SD-HD), and
2) long-duration, lesser total days’ supply (LD-LD) post-operative prescription patterns. Significantly higher costs
and health care utilization for both hip-related and non-hip-related variables were consistently identified in the
SD-HD group.
Conclusions: Long-term opioid prescription use has been identified as a concern, but our findings demonstrate
that LD-LD post-operative opioid management for hip surgery recipients was associated with lower costs and utilization.
Whether these management patterns were a reflection of pre-operative health status, impacted pain-related outcomes, or
can be replicated in other orthopedic procedures remains a consideration for future studies.
Trial registration: NA.
Keywords: Femoroacetabular impingement, Surgery, Opioid management
Background
In March 2016, the Centers for Disease Control and
Prevention (CDC) published a series of guidelines de-
signed to improve communication between health care
practitioners and patients regarding the risks and bene-
fits of opioid drug therapy [1]. Within the guidelines,
suggestions associated with dosage, duration, follow-up,
and discontinuation received emphases, specifically
regarding the lowest effective dosage [2]. The CDC had
been prompted to act to address the increasing number
of overdose deaths and use/abuse escalations in those
with non-cancer-related pain [3]. Whereas recommenda-
tions for use of a multimodal therapeutic approach that
includes opioids are available for acute, general surgery
peri-operative management [4], opioid management
strategies for intermediate- to long-term post-surgical
musculoskeletal pain have not been clearly defined. Judi-
cious medication management, including the use of opi-
oid therapies, is recommended [5], but prescription
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patterns, dosing, and timing appear to vary markedly
among prescribers.
In addition, whereas immediate pain management
strategies for total hip arthroplasty have been well ex-
plored peri-operatively [6], long-term strategies remains
mostly uninvestigated. Non-arthroplasty-related hip sur-
geries are on the rise, with femoroacetabular impingement
(FAI) syndrome surgery exhibiting an 18-fold increase in
the United States [7]. Long-term non-arthroplasty-related
pain management is mostly unexplored. To our know-
ledge, despite the notable escalation in surgery rates, only
four studies [8–11] have discussed pain medication man-
agement strategies for non-arthroplasty orthopedic inter-
ventions such as FAI. All involved (acute) peri-operative
opioid management only.
In light of the recent charge of reducing opioid use
published by the CDC [1] and because of the escalating
levels of non-arthroplasty hip surgeries in the United
States, exploration of post-operative opioid prescription
patterns is warranted. We targeted patients within the
Military Health System because of existing mechanisms
associated with data capture pre- and post-operatively
and higher likelihood of homogeneity of care. Our pri-
mary aim was to investigate a subgrouping scheme asso-
ciated with post-operative opioid prescription strategies
(number of opioid prescriptions and longevity of the
prescription) toward direct (hip-related) and indirect
(total care) health care utilization and costs. We hypoth-
esized that the clustered subgroup patients who received
more prescriptions of opioids over longer durations
would be associated with greater direct and indirect
utilization and costs. Our study has potential to add to
the existing literature because optimal patterns of opioid
prescription have yet to be explored for many common
musculoskeletal surgeries. Additionally, these findings
could contribute to improving recognition of opioid pre-
scription patterns and how these are associated with
downstream costs and utilization.
Methods
Reporting guidelines
The study design warranted the use of the REporting of
studies Conducted using Observational Routinely col-
lected health Data (RECORD) initiative [12]. RECORD
was created to improve the transparent reporting of
observational studies—such as cohort, case-control, and
cross-sectional studies—and recommend minimum re-
porting standards for observational studies [12, 13].
Ethical approval of our study was given by the Institu-
tional Review Board at Brooke Army Medical Center.
Study design
The study was an observational case series of routine
clinical practices of Department of Defense (DOD)
beneficiaries, seen in both military and civilian network
clinics, who received non-arthroplasty hip-related sur-
gery. Data were collected from July 1, 2003, through
June 30, 2015, and covered 12-month pre-operative and
24-month post-operative timelines.
Data sourcing
Data were pulled from the Military Health System Data
Repository (MDR), which serves as the centralized data
repository for all Defense Health Agency corporate
health care data. MDR data are collected from a world-
wide network of more than 260 DOD health care facilities
and non-DOD entities. Data include every person-level
interaction for health care, both inpatient and outpatient.
MDR data are carefully processed by the Defense Health
Agency, updated monthly, and available to a select group
of researchers with special data usage agreements.
Selection of variables
Sample
To keep the sample homogenous, we attempted to iden-
tify a specific hip surgical population, FAI syndrome, for
which the number of surgeries performed has increased
remarkably [7]. Since a dedicated International Classifi-
cation of Diseases (ICD)-9 code for this condition does
not exist, we identified surgical procedure codes most
often used for this condition, excluded any surgical
codes associated with arthroplasty, and then excluded
any non-FAI conditions that might also receive this
same surgical procedure in the 12 months before the
surgery (e.g., hip osteoarthritis; avascular necrosis of the
hip; hip fracture; osteomyelitis of the hip; malignant neo-




To better understand the pattern of opioid prescription,
we a priori clustered two variables: 1) the number of
days post-operative to the last opioid prescription (date
of last opioid prescription – date of surgery), and 2) the
days’ supply variable from MDR, which measures the
number of days that the medication covers if taken as
prescribed, representing the dose based on a multiple of
the strength and daily frequency of each individual intake.
Cluster analysis—also called segmentation or taxonomy
analysis—is an explorative approach that identifies
grouping structures within data [14]. Cluster analysis
identifies homogenous subgroups in situations where
the grouping is not previously known.
Descriptive variables
Age, sex, military service branch, socioeconomic status,
hip surgery type (closed or open), and whether the
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surgery occurred in a network or military health facility
were collected to describe the sample. We also examined
total health care utilization in the prior 12 months, be-
cause the daily number of health care services during
the prior year is related to higher use after a specific
event such as surgery (service is defined as a medical
visit for any health care service) [15]. Our health care
utilization variables differentiated between hip-related
and non-hip-related visits that were coded within the
MDR.
Comorbidities
We identified a list of medical comorbidities within the
MDR that we found to have a significant association
with orthopedic injury and surgical outcomes. We cap-
tured pre-operative systemic arthropathy (osteoarthritis
or other forms of systemic disease, rheumatoid or psori-
atic arthritis), chronic pain, metabolic disorders, sub-
stance abuse, insomnia, mental health problems, and
post-traumatic stress disorder.
Outcome variables
We captured variables associated with post-operative
health care utilization and costs. In the MDR, costs are
sub-categorized by total costs of all health care interven-
tions (which include hip-related and non-hip-related
costs) and total costs of hip-related health care interven-
tions—each broken down by provider type. Visits were
structured by provider, similarly to costs.
Opioid prescriptions
We expected a majority of opioid prescriptions peri-
operatively (day 0 to day 3). For this study, we were in-
terested in non-acute, post-operative opioid manage-
ment strategies. Subsequently, we removed all opioid
prescriptions that were provided at the index date of
surgery through day 3, post-operation. All opioid pre-
scriptions represented in the data are those that oc-
curred from day 4 (post-operative) to month 24.
Missing values
Data in the MDR are processed weekly. Part of the pro-
cessing involves encounter validation and replacement
of missing values prior to release to public consumers, re-
searchers, or policy makers. Within the dataset, 98.11% of
cases had complete data and 99.83% of values were
complete. Because these missing data were marginal, we
opted not to impute data.
Data analysis
There were three main analyses used in this study. First,
we used two-step cluster analysis to identify post-operative
opioid use subgroupings after running pre-clustering
methods. This method is designed to reveal natural
subgroupings (or clusters) within a dataset that would
otherwise not be apparent. Two-step cluster analysis
handles scale and ordinal data and automatically selects
the number of subgroups using the Bayesian informa-
tion criterion [16].
Secondly, we used descriptive statistics to describe the
groups that were divided by opioid use clusters and
comparatively analyzed both groups using SPSS version
23.0. Nominal variables were compared using chi-square
analyses. Continuous variables were evaluated using linear
mixed effects modeling.
Lastly, we used linear mixed effects modeling to com-
pare costs and utilization rates between the opioid use-
based, clustered groups. Linear mixed effects modeling
methods are flexible, model individual change, and ac-
commodate for missing data (when present). We ran
two analyses, unadjusted and adjusted, in which we con-
trolled for well-represented baseline characteristics that
were significantly different. For all analyses, a p-value < 0.05
was used to determine statistical significance.
Results
In total, 1219 surgical recipients were included in the
planned analyses. Clustering identified two distinct
post-operative opioid prescription subgroups: 1) short-
duration, high total days’ supply (SD-HD: N = 850), and
2) long-duration, less total days’ supply (LD-LD: N = 369).
The overall trend was that the SD-HD subgroup had more
pre-operative comorbidities, opioid prescriptions, and
total days of opioid pain medications. That subgroup was
also younger and had higher proportions of heavy pre-
operative health care utilization. Baseline differences
among clustered groups are reported in Table 1.
Table 2 involves linear mixed effects modeling and
outlines unadjusted differences in costs and health care
utilization. Statistically significant between-subgroup dif-
ferences were noted with total health care visits and
costs as well as total hip-related health care visits and
costs—all indicating higher costs and utilization in indi-
viduals with SD-HD. Those in the SD-HD group also
had significantly higher total days’ supply of all pain-
related medications. Fig. 1 provides a graphical representa-
tion of all healthcare costs by group comparison whereas
Fig. 2 represents the differences in hip related costs.
Table 3 involves linear mixed effects modeling and re-
flects adjusted differences in costs and health care
utilization, using the controls of age and pre-operative
opioid use, pre-operative metabolic syndrome, and pre-
operative health utilization behaviors. Findings were
similar to the unadjusted totals, with between-subgroup
differences in total days’ supply of pain medications,
total health care visits and costs, and total hip-related
health care visits and costs—all indicating significantly
higher costs and utilization in individuals with SD-HD.
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Discussion
Our study investigated an empirically determined sub-
grouping scheme based on post-operative opioid pre-
scription strategies and compared the derived subgroups
on direct (hip-related) and indirect (total care) health
care utilization and costs. We targeted individuals seeking
care in the Military Health System who had undergone
non-arthroplasty orthopedic hip surgery in hopes of
homogenizing the patient population and care processes.
Furthermore, the Military Health System is the closest
example of a single-payer system in the United States,
which provides an additional advantage when analyzing
care-related trends. Rather than attempt to authoritatively
define subgroups, cluster analysis identified distinct post-
operative prescription patterns as 1) SD-HD and 2) LD-LD.
Patient characteristics, costs, and health care utilization
Table 1 Comparative analyses between clustered groups (baseline) N = 1219
Variable Group 1 short-term duration,
higher total days’ supply
N = 850
Group 2 long-term duration,
lower total days’ supply
N = 369
P-value
aPre-op opioid prescription 765 = yes 351 = yes <0.01
72 = no 14 = no
13 =missing 4 =missing
aSex 471 =male 213 =male 0.46
379 = female 156 = female
Age 31.38 (7.83) 32.44 (7.98) 0.03
aMilitary service branch 389 = Army 149 = Army 0.07
13 = Coast Guard 5 = Coast Guard
197 = Air Force 110 = Air Force
110 =Marines 35 =Marines
139 = Navy 68 = Navy
2 = Other 2 = Other
aOfficer/enlisted 687 = enlisted 346 = enlisted 0.04
163 = officer 23 = officer
aHip surgery type 767 = closed 430 = closed 0.64
83 = open 26 = open
Network or MHS 475 =MHS 194 = MHS 0.28
375 = network 175 = network
Number of opioid prescriptions
Pre-op 3.19 (4.43) 2.18 (1.85) <0.01
Post-op 7.39 (2.21) 2.21 (1.95) <0.01
Last recorded opioid prescription (days from surgery) 38.71 (52.91) 406.24 (152.61) <0.01
aArthropathy (pre-op) 573 = no 243 = no 0.59
277 = yes 126 = yes
aMetabolic disorders (pre-op) 754 = no 344 = no 0.02
96 = yes 25 = yes
aSubstance abuse (pre-op) 707 = no 319 = no 0.15
143 = yes 50 = yes
aCardiac problems (pre-op) 784 = no 339 = no 0.83
66 = yes 30 = yes
aInsomnia (pre-op) 794 = no 352 = no 0.26
53 = yes 17 = yes
aHeavy pre-op health utilizers 380 = no 212 = no <0.01
467 = yes 157 = yes
aRepresents use of chi-square analyses. All continuous analyses used linear mixed effects modeling
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were different depending on group allocation, and there are
a number of potential reasons for these findings.
In the literature, we found no data on post-operative
opioid prescription patterns for non-arthroplasty ortho-
pedic hip surgical management and only limited infor-
mation overall on strategies of opioid prescription
patterns for any form of surgery. For our study, we used
Bayesian information criteria to define homogenous sub-
groups of opioid prescriptions, and two strong, well-
defined, distinct patterns emerged. In this cohort, those
in the SD-HD subgroup exhibited higher overall health
care costs and utilization, whether it was related to the hip
or not. In our initial hypothesis, we assumed that longer-
term post-operative use would be grouped together with
higher doses of opioid prescriptions, but this was not the
case when subgroups were determined empirically.
Longer-term use was related to fewer overall prescriptions
and days’ supply of opioids; and conversely, shorter-term
use was related to more prescriptions and days’ total sup-
ply. We consider four propositions on the unique patterns
that were robustly identified by the subgroups.
Proposition one
We suggest that the post-operative opioid prescription
patterns observed are reflective of pre-operative comorbid
conditions. It is well documented that sociodemographic
factors, pain, prior drug use, genetics, environmental fac-
tors, psychosocial problems, and established addictive be-
haviors (e.g., alcohol abuse) increase the risk of opioid
drug use [17]. Concomitant psychosocial problems such
Table 2 Unadjusted bivariate analyses of post-operative outcomes between clustered groups
Variable Degrees of freedom Group 1 short-term duration,
higher total days’ supply
N = 850
Group 2 long-term duration,
lower total days’ supply
N = 369
P-value
Total health care visits (post-op) 1217 96.99 (68.26) 76.99 (54.17) <0.01
Total health care costs (post-op) 1217 $31,944.44 ($27,473.44) $27,765.60 ($33,075.09) 0.02
Total hip-related visits (post-op) 1217 32.87 (28.90) 25.12 (23.49) <0.01
Total hip-related costs (post-op) 1217 $16,888.09 ($15,522.37) $14,153.19 ($18,670.25) 0.02
Total days’ supply of all pain-related medications 1217 1148.00 (1138.01) 885.34 (927.60) <0.01
Cost of pain meds (post-op) 1217 $859.30 ($3682.92) $680.55 ($3853.24) 0.44
Bolded p-values reflect statistical significance <0.05. All analyses involve linear mixed effects modeling
Fig. 1 Bar graph representing unadjusted total costs of care divided by subgroups of opioid prescription
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as chronic pain syndrome, depression, anxiety, and other
forms of social phobia, especially at a younger age, are also
stronger predictors of opioid use and abuse [18]. Within
our study, those in the SD-HD subgroup had higher pro-
portions of pre-operative mental health diagnoses and
substance abuse histories and were younger on average.
The SD-HD prescription pattern observed in this cohort
may reflect a management process in which health care
provider prescription pattern was reactionary to those
conditions.
Proposition two
The SD-HD subgroup was likely associated with the pre-
operative opioid use patterns of its patients. Generalized
risks of opioid misuse, abuse, dependence, or addiction
are well studied; and prior opioid use also leads to an in-
crease in tolerance of opioids (or a state of adaptation)
[18]. Prior exposure to an opioid can result in a dimin-
ution of one or more opioid effects over time and reduces
the clinical effect of the prescription [19]. When analyzing
our pre-operative data, we found that those in the SD-HD
subgroup had 1.01 more prescriptions (on average) and
15.56 more total days of opioid medication than those
in the LD-LD subgroup. This proposition is consistent
with others who have suggested the risk of persistent
post-operative pain after different forms of surgery is
associated with higher levels of pre-operative opioid
use [20, 21].
Fig. 2 Bar graph representing unadjusted total hip-related costs of care divided by subgroups of opioid prescription
Table 3 Adjusted bivariate analyses of post-operative outcomes between clustered groups
Variable Degrees of freedom Group 1 short-term duration,
higher total days’ supply
N = 850
Group 2 long-term duration,
lower total days’ supply
N = 369
P-value
Total health care visits (post-op) 1202 97.51 (68.44) 76.88 (54.09) <0.01
Total health care costs (post-op) 1202 13,155.48 (9369.88) 10,721.88 (10,570.18) <0.01
Total hip-related visits (post-op) 1202 32.94 (28.93) 25.26 (23.57) <0.01
Total hip-related costs (post-op) 1200 $16,891.10 ($15,581.68) $14,575.15 ($18,737.44) 0.03
Total days’ supply of all pain-related medications 1200 1,157.52 (1,143.02) 891.36 (930.34) <0.01
Cost of pain meds (post-op) 1202 $871.15 ($3,710.12) $679.09 ($3,871.75) 0.42
Bolded p-values reflect statistical significance <0.05. Includes linear mixed effects modeling with control for age and pre-operative opioid use, pre-operative
metabolic syndrome, and pre-operative health utilization behaviors
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Proposition three
We hypothesize that those in the LD-LD subgroup may
have benefitted more from opioids by receiving adequate
pain management, requiring fewer prescriptions over
time. Whereas the data regarding the number of pills or
strength of dosage related to a prescription were unavail-
able, we did have data on total days of medication, which
is a proxy measure that represents the number of days
that the medication covers if taken as prescribed (thus
representing the dose based on a multiple of the
strength and daily frequency of each individual intake).
This interpretation is consistent with our clinical experi-
ence and matches the decreased total pain medication
days seen in the LD-LD group. This theory deserves fur-
ther exploration as the idea of greater benefit from
longer-term prescriptions is a paradox given the current
climate for limiting opioid prescription. For example, on
average, LD-LD subgroup patients received opioid pre-
scriptions 400+ days post-operatively; yet, they had
lower overall health care utilization and costs.
Proposition four
We hypothesize that the higher costs and utilization are
associated with increased incidences of side effects in
the SD-HD subgroup. Previous work supports that costs
associated with opioid-related constipation for non-
cancer-related opioid recipients was nearly double that
of non-opioid-related constipation, and that inpatient
hospitalization odds were 2.3 times higher in those with
constipation than in those without [22]. Other side ef-
fects such as sedation, dizziness, nausea, vomiting, phys-
ical dependence, tolerance, and respiratory depression
may also lead to increased health care costs [23]. Unfor-
tunately, our dataset does not provide data on the most
common side effects or the temporal relationship of
these side effects to opioid utilization.
What do these findings mean for those prescribing
and receiving opioid medications post-operatively? We
argue that opioid prescription strategies require further
investigation into whether these subgroups replicate in
other conditions outside of hip surgery and outside a
single-payer system such as the Military Health System.
In addition, future work should determine whether these
subgroups are related to adequate patient report of pain
relief, habituation, or addiction. If these subgroups are
represented outside the Military Health System and in
other conditions, further exploration is needed to ex-
plore why the LD-LD group exhibited less health care
utilization and had lower costs.
Further, the relationship between true pain relief of
the groups should be explored to determination the as-
sociation of relief to lower utilization and costs. This is
especially important since managing long-term opioid
prescribing is a targeted objective of the CDC [1] and
the American Society of Interventional Pain Physicians
(ASIPP) [24], which has specifically targeted cases
involving >90 days. Further, costs and health care
utilization associated with opioid non-abusers may shed
further light on care patterns since previous work [25]
has shown that those who take opioids (at least one
opioid prescription) but do not abuse them incur $1800
more in costs versus those who receive no opioid pre-
scriptions. Our findings are similar and suggest that
those who receive SD-HD will also utilize hip-related
and non-hip-related health care at a higher rate, with
corresponding increases in costs.
Limitations
There are several limitations to this study. First, despite
our ability to incorporate pre-operative factors and cap-
ture patterns over a 24-month period, the study design
did not permit cause-and-effect statements to be made
about the identified subgroups. Second, the MDR pro-
vided no specifics on the type of opioid action (short- or
long-acting). Third, the MDR lacks patient-reported out-
comes; thus, we are unable to determine which opioid
strategy was related to better pain relief and health-related
outcomes. Fourth, measures such as chronic pain may fail
to represent fully all those with recognized chronic pain
conditions. Lastly, the information is limited to individuals
within the military payment system and may not be
generalizable to other health care environments.
Conclusions
Long-term opioid prescription use has been identified as a
concern, but our findings demonstrate that LD-LD post-
operative opioid management for hip surgery recipients
was associated with lower costs and utilization. These re-
sults suggest that opioid management strategies for other
common post-operative orthopedic procedures should be
investigated in a controlled fashion to determine whether
this subgroup pattern can be replicated and to better ex-
plore the effectiveness of prescription pattern on provid-
ing post-operative pain relief without excessive side effects
or fostering opioid abuse. Whether these management
patterns were a reflection of pre-operative health status,
were affected by pain-related outcomes, or can be repli-
cated in other orthopedic procedures remains a necessary
consideration for future studies.
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